![Eli Lilly lanza Baqsimi, el primer glucagón nasal para tratar la hipoglicemia severa. – Fundación Mi Diabetes Eli Lilly lanza Baqsimi, el primer glucagón nasal para tratar la hipoglicemia severa. – Fundación Mi Diabetes](https://www.midiabetes.cl/wp-content/uploads/2019/09/baqsimi-1074x780.png)
Eli Lilly lanza Baqsimi, el primer glucagón nasal para tratar la hipoglicemia severa. – Fundación Mi Diabetes
![New nasal spray launched in Canada to combat hypoglycemic shock in diabetics - Greater Victoria News New nasal spray launched in Canada to combat hypoglycemic shock in diabetics - Greater Victoria News](https://www.bpmcdn.com/f/files/victoria/import/2020-01/20257987_web1_preparing-the-dose_2.jpg;w=1200;h=794;mode=crop)
New nasal spray launched in Canada to combat hypoglycemic shock in diabetics - Greater Victoria News
News Today Channel - The FDA has approved Baqsimi, a nasally administered glucagon, for treatment of severe hypoglycemia in people with diabetes four years & older. It is administered like a nasal
![Eli Lilly lanza Baqsimi, el primer glucagón nasal para tratar la hipoglicemia severa. – Fundación Mi Diabetes Eli Lilly lanza Baqsimi, el primer glucagón nasal para tratar la hipoglicemia severa. – Fundación Mi Diabetes](https://www.midiabetes.cl/wp-content/uploads/2019/09/baqsimi2.png)